Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Harvard Business School
Johnson and Johnson
Federal Trade Commission

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,956,179

« Back to Dashboard

Title:Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A.sub.2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
Inventor(s): Zablocki; Jeff (Mountain View, CA), Elzein; Elfatih (Fremont, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jan 13, 2010
Application Number:12/687,077
Claims:1. A method of synthesizing a compound of the formula (4): ##STR00025## comprising contacting a compound of the formula (2): ##STR00026## with an excess of ethyl 2-formyl-3-oxopropionate optionally in the presence of acid.

2. The method of claim 1, wherein the contacting is conducted in ethanol.

3. The method of claim 1, wherein the acid is HCl up to 0.1 molar equivalent is used.

4. The method of claim 3, wherein the contacting takes place at reflux.

5. The method of claim 1, wherein about a 5-10 fold molar excess ethyl 2-formyl-3-oxoproionate is used.

6. The method of claim 5, wherein about a 6.8-7.5 fold molar excess of ethyl 2-formyl-3-oxoproionate is used.

7. The method of claim 6, wherein the compound of the formula (4) is isolated by (a) cooling the completed reaction mixture to approximately 10.degree. C., (b) filtering, (c) washing the contents of the filter with ethanol, and (d) drying the solid that remains under vacuum at a temperature that does not exceed 40.degree. C.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.